PPD Declares Third Quarter Dividend

WILMINGTON, N.C.--(Business Wire)--
PPD, Inc. (Nasdaq: PPDI) today announced that its board of
directors declared a cash dividend for the third quarter of 2008 under
its annual cash dividend policy. The quarterly cash dividend will
equal $0.10 per share. The record date for the third quarter dividend
is September 15, 2008, and the payment date is September 29, 2008. The
annual cash dividend policy and the payment of future quarterly cash
dividends under that policy are subject to the continuing
determination by the board of directors that the policy remains in the
best interests of the company's shareholders and in compliance with
applicable laws and agreements.

PPD is a leading global contract research organization providing
discovery, development and post-approval services as well as compound
partnering programs. Our clients and partners include pharmaceutical,
biotechnology, medical device, academic and government organizations.
With offices in 31 countries and more than 10,400 professionals
worldwide, PPD applies innovative technologies, therapeutic expertise
and a commitment to quality to help its clients and partners maximize
returns on their R&D investments and accelerate the delivery of safe
and effective therapeutics to patients. For more information, visit
our Web site at http://www.ppdi.com.

Except for historical information, all of the statements,
expectations and assumptions, including expectations and assumptions
about the payment of future cash dividends under the annual dividend
policy, contained in this news release are forward-looking statements
that involve a number of risks and uncertainties. Although PPD
attempts to be accurate in making these forward-looking statements, it
is possible that future circumstances might differ from the
assumptions on which such statements are based. In addition, other
important factors which could cause results to differ materially
include the following: risks that we may not continue our dividend
policy; economic conditions and outsourcing trends in the
pharmaceutical, biotechnology and medical device industries and
government-sponsored research sector; success in sales growth; loss of
large contracts; competition within the outsourcing industry; the
ability to attract and retain key personnel; dependence on
collaborative relationships; rapid technological advances that make
our products and services less competitive; and the other risk factors
set forth from time to time in the SEC filings for PPD, copies of
which are available free of charge upon request from the PPD investor
relations department.

PPD, Inc.
Dan Darazsdi, 910-558-7915
dan.darazsdi@wilm.ppdi.com
or
Luke Heagle, 910-558-7585
luke.heagle@wilm.ppdi.com

Copyright Business Wire 2008